Macrocycle Therapeutics to Treat Life-threatening Diseases

被引：3
作者：
Batur, Gokhan [1 ]
Ermert, Philipp [1 ]
Zimmermann, Johann [1 ]
Obrecht, Daniel [1 ]
机构：
[1] Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil, Switzerland
来源：
CHIMIA | 2021年 / 75卷 / 06期
关键词：
Antibiotic; Breast cancer; CXCR4; inhibitor; Macrocycle; Protein epitope mimetic; SYNTHETIC PEPTIDE; CXCR4; POTENT; CHEMOTHERAPY; MOBILIZATION; METASTASIS; ANTAGONIST; INHIBITOR; DISCOVERY; THANATIN;
D O I：
10.2533/chimia.2021.508
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.
引用
收藏
页码：508 / 513
页数：6
相关论文
共 46 条
  • [21] Murepavadin: a new antibiotic class in the pipeline
    Martin-Loeches, Ignacio
    Dale, Glenn E.
    Torres, Antoni
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (04) : 259 - 268
  • [22] "They could be good players if they trained": exploring the football discourse of five-year-old boys and girls
    Martinez-Garcia, Maria-Lindsay
    Rodriguez-Menendez, Carmen
    [J]. JOURNAL OF GENDER STUDIES, 2021, 30 (06) : 737 - 751
  • [23] Thanatin Impairs Lipopolysaccharide Transport Complex Assembly by Targeting LptC-LptA Interaction and Decreasing LptA Stability
    Moura, Elisabete C. C. M.
    Baeta, Tiago
    Romanelli, Alessandra
    Laguri, Cedric
    Martorana, Alessandra M.
    Erba, Emanuele
    Simorre, Jean-Pierre
    Sperandeo, Paola
    Polissi, Alessandra
    [J]. FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [24] Involvement of chemokine receptors in breast cancer metastasis
    Müller, A
    Homey, B
    Soto, H
    Ge, NF
    Catron, D
    Buchanan, ME
    McClanahan, T
    Murphy, E
    Yuan, W
    Wagner, SN
    Barrera, JL
    Mohar, A
    Verástegui, E
    Zlotnik, A
    [J]. NATURE, 2001, 410 (6824) : 50 - 56
  • [25] ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVITY OF A NOVEL SYNTHETIC PEPTIDE, T22 ([TYR-5,12, LYS-7]POLYPHEMUSIN II) - A POSSIBLE INHIBITOR OF VIRUS-CELL FUSION
    NAKASHIMA, H
    MASUDA, M
    MURAKAMI, T
    KOYANAGI, Y
    MATSUMOTO, A
    FUJII, N
    YAMAMOTO, N
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) : 1249 - 1255
  • [26] Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets
    Naylor, Matthew R.
    Bockus, Andrew T.
    Blanco, Maria-Jesus
    Lokey, R. Scott
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2017, 38 : 141 - 147
  • [27] Obrecht D., AAC ANN C 2021 POST AAC ANN C 2021 POST
  • [28] Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4)
    Oishi, Shinya
    Fujii, Nobutaka
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2012, 10 (30) : 5720 - 5731
  • [29] Over B, 2016, NAT CHEM BIOL, V12, P1065, DOI [10.1038/nchembio.2203, 10.1038/NCHEMBIO.2203]
  • [30] The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential
    Peng, Dian
    Cao, Bin
    Zhou, Ying-Jun
    Long, Ya-Qiu
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 149 : 148 - 169
12345